Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chemotherapy for metastatic melanoma was performed in 80 consecutive evaluable patients. DTIC, BCNU and CCNU produced responses in 28% of patients, alone or in combination with each other. Three of 62 patients treated with DTIC remain free of tumor, off therapy at 18-36 months following objective regression of metastases. Chemotherapy with commercially available drugs continued to be uniformly unsuccessful. DTIC was used successfully in treatment of extensive extracranial disease, including one patient with metastatic melanoma during pregnancy. Cerebral metastases were the sole or major cause of death in 8/9 patients who relapsed following control with DTIC for nine months or longer, and one patient developed a carcinoma of the breast following therapy with DTIC and BCNU. Remission was induced in two patients with intralesional BCG, after prior attempts to control metastases with DTIC and combination chemotherapy.
 ...
PMID:Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). 460 84

The responses of four murine lymphomata, transplanted in their syngeneic hosts and differing widely in their biological properties such as tendency to metastasize and "strength" of tumour specific antigen, to immunotherapy, were investigated. Following the injection of a known number of tumour cells, the mice were treated either by administration of irradiated tumour cells, living BCG or both. In general, the response to BCG alone was small even in the most responsive tumours, irradiated cells were more effective and the best results were obtained by a combination of the two procedures. "Cures" were only obtained with the most antigenic of the tumours tested and then only when the live tumour cells were inoculated intraperitoneally. The effect of these treatments on the rate of growth of tumour when the cells were given subcutaneously was small but the rate at which metastatic spread occurred from the s.c. site was slowed and for one of these tumours this was quite marked.
 ...
PMID:Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour. 504 41

Fourteen patients with advanced renal carcinoma were treated with Adriamycin 40 mg/m2 I.V., bleomycin 15 U/m2 I.V., vincristine 2 mg I.V., cyclophosphamide 200 mg/m2 p.o. x 4 days, and BCG by scarification every 4 weeks. Of 13 evaluable patients, three (23%) achieved partial remissions on therapy, five (39%) were improved, and three were stable. Responding disease sites included lung and pleural metastases, and an abdominal mass. Median duration of response was 4 months. Median survival was 8.5 months, but the partial responders survived for 13, 17, and 19 months. Toxicity included nausea and vomiting (31%), leukopenia (8%), thrombocytopenia (8%), diarrhea (15%), alopecia (8%), stomatitis (8%), and paresthesias (8%). This well-tolerated stomatitis (8%), and paresthesias (8%). This well-tolerated chemoimmunotherapy regimen has moderate activity in renal carcinoma and deserves further evaluation.
 ...
PMID:Combination chemoimmunotherapy for advanced renal carcinoma with Adriamycin, bleomycin, vincristine, cyclophosphamide, plus BCG. 616 7

Guniea pigs with established (7 or 14 days old) syngeneic dermal tumors and metastases in the draining lymph nodes were unsuccessfully treated by excision of the dermal tumors and specific immunization. The vaccines consisted of killed BCG in oil in an emulsified form admixed with mitomycin C treated or irradiated tumor cells. The therapeutic failure to eradicate the metastases was overcome by an additional treatment with a single injection of cyclophosphamide prior to excision of the primary tumor and immunization. It is assumed that cyclophosphamide destroys suppressor elements in the tumor-bearing guinea pigs and, in this way, augments the therapeutic effects of specific immunization.
 ...
PMID:Effect of a single injection of cyclophosphamide on immunization therapy of metastases remaining after excision of dermal primary tumors in guinea pigs. 623 13

Twenty-nine patients with osteogenic osteosarcoma of a limb underwent both pulmonary radiotherapy and chemotherapy immediately after treatment of the primary tumor, mainly by radical surgery or radiotherapy (80 grays/tumor). Chemotherapy consisted of alternate A and B cycles every four weeks and BCG scarifications between cycles. Cycle A combines vincristine, ameticine, methotrexate and folinic acid; cycle B consists of adriamycin, vincristine, imidazole carboxamide and cyclophosphamide. A 20 gray irradiation was delivered to the thorax between the first A and B cycles. 50% of patients had no local recurrence or metastases after three years. 70% are alive at three years. Toxicity of this protocol is mainly hematologic and bronchopulmonary (with one fatal infection). Alopecia and minor digestive toxicity were recorded in all patients. Severe cardiotoxicity was seen in only one case. Longer follow-up is needed to evaluate long-term toxicity, particularly bronchopulmonary side-effects.
 ...
PMID:[Adjuvant therapy of osteogenic osteosarcomas of the limb: results of the SO4 78 trial]. 629 Nov 57

Fifty-two patients with locally advanced primary breast cancer (T3, T4, N2, N3) but no evidence of distant metastases were treated with three cycles of combination chemotherapy. The regimen consisted of 5-fluorouracil, Adriamycin, cyclophosphamide, and Bacillus Calmette-Guerin (FAC-BCG), followed by local therapy (simple mastectomy and/or radiotherapy to the breast/chest wall and the regional lymphatic system) and adjuvant chemotherapy for two full years. The results were compared with those in an historical control group of 52 patients matched for initial stage of disease who were treated by a simple mastectomy and postoperative radiotherapy only. Forty-nine (94%) of 52 FAC-treated patients and 48 (92%) of the control patients became free of clinically detectable disease. At the median follow-up time of 56 months, 37.5% of the FAC-treated patients and 19.5% of the control patients had remained free of disease. FAC-treated patients who completed 2 years of therapy and in whom adjuvant chemotherapy was started promptly after local treatment had a 48% disease-free survival rate of 4 years. In those in whom the initial manifestation was supraclavicular involvement, the estimated 5-year disease-free survival rate was 42% for patients treated with FAC and 9% for control patients. There were local recurrences in 25% of FAC-treated patients and 23% of control patients (not significant). Distant metastases developed in 50% of FAC-treated patients and 77% of control patients (p less than 0.01). The median disease-free interval was 25 months in the FAC-treated group and 11 months in the control group (p = 0.025). The greatest improvement in prognosis was in patients with supraclavicular involvement; the median disease-free survival was 26 months in FAC-treated patients and 6 months in the control group (p = 0.007). This multimodal approach effectively renders the majority of patients with locoregionally advanced breast cancer free of disease and prolongs the disease-free survival period.
 ...
PMID:Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. 634 12

Combined prophylactic treatment by total body irradiation and BCG produce an increase in lung metastasis incidence and pleural effusions in a syngeneic murine tumor model. The prophylactic effect of BCG on metastasis formation is abolished independently of the order of pretreatments. Several possible causative mechanisms underlying this phenomenon and the clinical implications are discussed.
Clin Exp Metastasis
PMID:Increased incidence of lung metastases of sarcoma 276 bearing XVII/Berlin mice after total body irradiation and BCG. 640 Apr 34

Management of the superficial bladder cancer patient consists of two complementary but separate therapeutic goals: treatment of the existing tumor(s) and prevention of tumor recurrence. At present, the stage, grade, and multicentricity are the major determinants in the natural and therapeutic history of the disease. Although intravesical instillation of chemotherapeutic agents has been used for greater than 20 years, neither its exact role nor the optimal dose or schedule of administration have been established. To date, no dramatic differences in efficacy between the agents commonly used for intravesical chemotherapy, either as definitive therapy or prophylaxis, have been appreciated. These agents do appear to lower the recurrence rate as well as extend the disease-free interval. Since the most thorough experience is with thiotepa, it is the drug against which other agents should be compared in terms of both efficacy and toxicologic evaluation. Different administration schedules and methodologies need further study, such as the utility of continuous bladder irrigation, the use of sequential chemotherapeutic agents to gain cell synchronization, and the use of multiple drug regimens. Because there are multiple factors that influence the occurrence and recurrence of bladder cancer, combined modality therapy deserves testing. Modes of therapy that could be used together because they act through different mechanisms are intravesical chemotherapy, radioactive needle implants, carcinogen modifiers such as pyridoxine, chemoprotective agents such as retinoic acid, and immune stimulants such as BCG. These studies should be performed in a randomized prospective controlled fashion, which may require cooperative multi-institutional involvement to accrue adequate numbers of patients. At this time there are a number of important questions that remain to be answered concerning the treatment of superficial bladder cancer: (1) does this mode of therapy affect overall survival, (2) does prophylactic intravesical chemotherapy alter the incidence of subsequent muscle invasive disease, (3) does intravesical chemotherapy alter the sites, incidence, or responsiveness to systemic chemotherapy of subsequent metastatic disease, and (4) and what is the optimal timing and duration of prophylactic therapy from a cost-effectiveness standpoint?
 ...
PMID:The biology and treatment of superficial bladder cancer. 642 17

The prophylactic effect of maltose tetrapalmitate (MTP), a newly developed non specific immunoadjuvant in preventing or delaying bladder cancer induction by N-[4(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) or in reducing the growth rate of the induced tumor was compared to other well-known immunoadjuvants (BCG, C. parvum, levamisole and pyran copolymer). The evaluation of the prophylactic role of immunoadjuvants demonstrated that MTP, levamisole and C. parvum were the most effective in prolonging animal survival. MTP was found superior to either of them in reducing the tumor size. The development of lung metastasis was lower in the group receiving MTP or C. parvum. Next, MTP was studied for its therapeutic effect against primary FANFT induced tumor. The subcutaneous (s.c.) and oral routes of MTP administration and their combination with intravesical route were tried. Combinations of intravesical with s.c. or oral MTP were most effective in reducing tumor size, obtaining lower metastases along with greater mononuclear lymphocyte infiltration in the primary tumor.
 ...
PMID:Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors. 646 59

In a 48-year-old female patient 9 months after excision of a nodular melanoma on the back, multiple cutaneous, subcutaneous and lymph node metastases developed. Thereafter diffuse melanosis developed together with ocular metastatic involvement during immunochemotherapy with BCG and dacarbazine (DTIC). Most of the cutaneous metastases disappeared spontaneously with halo formation, while new nodes formed. The patient survived with disseminated melanoma more than 2 1/2 years without cytostatic therapy, before she died from intestinal metastases.
 ...
PMID:[Diffuse melanosis with generalized and ocular metastasis in malignant melanoma]. 646 36


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>